Drug-Induced Liver Injury Is a Major Risk for New Drugs
- 1 July 2015
- journal article
- Published by S. Karger AG in Digestive Diseases
- Vol. 33 (4), 458-463
- https://doi.org/10.1159/000374089
Abstract
Drug-induced liver injury (DILI), a relatively rare condition, is nevertheless a major reason for not approving a drug in development or for removing one already marketed. With a specific diagnostic biomarker lacking, finding elevated serum enzyme [alanine aminotransferase (ALT), aspartate aminotransferase and alkaline phosphatase] activities remains an initial signal for incipient liver injury. Enzyme elevations alone may not be harmful, but if caused by a drug and followed by jaundice (called ‘Hy's law') there is a high possibility of serious DILI. In 1997 several drugs were approved by the Food and Drug Administration (FDA) of the USA that were later withdrawn from the market for serious liver toxicity. New drugs in development are now required to be monitored for liver injury, and the data is to be considered in the approval decision. A program called e-DISH (evaluation of drug-induced serious hepatotoxicity) was introduced in 2004 to aid medical reviewers to select from all subjects studied those few who show nontrivial liver injury and estimate the most likely cause. The threshold of enzyme elevation comprising a warning for possibly serious DILI is uncertain, although generally accepted as 3-5 times the ‘upper limit of normal'. The new direct-acting antiviral agents for treating chronic hepatitis C virus, which often lead to a reduction of elevated ALTs, mandate that a later increase without viral breakthrough be compared to the new on-treatment level of values. The drug may be discontinued or interrupted for evaluation to exclude other possible causes of liver injury. The FDA has approved no drug since 1997 that has been withdrawn later because of serious hepatotoxicity.Keywords
This publication has 13 references indexed in Scilit:
- Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and ChallengesDrug Safety, 2014
- Drug-Induced Liver Injury and Drug Development: Industry PerspectiveSeminars in Liver Disease, 2014
- Drug-induced Acute Liver FailureClinics in Liver Disease, 2013
- Drugs in development for chronic hepatitis C: a promising futureExpert Opinion on Biological Therapy, 2011
- Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histologyHepatology, 2009
- Re‐evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large‐scale population studyLiver International, 2006
- Hy's law: predicting serious hepatotoxicityPharmacoepidemiology and Drug Safety, 2006
- Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: Case reports with positive rechallengeJournal of Clinical Epidemiology, 1993
- Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuriesJournal of Clinical Epidemiology, 1993
- Criteria of drug-induced liver disorders: Report of an International Consensus MeetingJournal of Hepatology, 1990